Poly Medicure Q1 FY27: consol revenue up 30% YoY, PAT down 8%
POLYMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts less than Nifty Smallcap 250 and 0.8 pts less than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Board approved Q1 FY27 unaudited results. Standalone revenue from operations rose about 12% YoY to Rs 431 crore, PAT nearly flat at Rs 88 crore. Consolidated revenue surged about 30% YoY to Rs 525 crore, but PAT fell about 8% to Rs 85 crore. Also granted 1,476 ESOP options at Rs 100 each, allotted 1,975 shares, reappointed cost auditor Jai Prakash and Company for FY 2026-27, and accepted Deputy Company Secretary Ravi Prakash resignation effective 10 August 2026.
Mixed quarter with strong consolidated topline but softer PAT. Minor equity dilution from ESOPs. Key managerial personnel exit noted.